OG Anunoby Wants You to Take Your Cat to the Vet

Royal Canin and VCA Animal Hospitals (Mars Petcare/Mars Veterinary Health) are launching a cat preventive-care push with NBA player OG Anunoby tied to Aug. 22 “National Take Your Cat to the Vet Day.” Mars Veterinary Health data using 3M+ U.S. pets shows cats are a smaller share of visits (>20% of pets seen) and visit less often (~2 vs ~3 visits/year for dogs), with a 26% decline in visits from under-1 to ages 1–<3; among young adult cats, nearly 30% had dental calculus, 10% were overweight, and ~10% had gingivitis. The initiative is educational/marketing-focused and unlikely to materially move markets.

Analysis

This is more a share-of-mind campaign than a near-term earnings event. The only economically meaningful angle is whether Mars can lift feline vet-utilization enough to improve attach rates for diagnostics, dental, wellness plans, and prescription nutrition; those are higher-margin than commodity pet food and can matter at the ecosystem level even if the top-line effect is slow to show up.

The public-market beneficiaries are the picks-and-shovels names tied to clinic utilization and preventive care economics, not Mars itself. IDEXX and Zoetis have the cleanest leverage if more cats are brought in for screening and chronic-condition detection, while pet-insurance names could see longer-cycle claim growth if earlier detection converts latent issues into managed care rather than emergency events. The loser, if any, is the “wait until sick” behavior that suppresses recurring spend; independent clinics and retailers with lower wellness-program penetration could lag if Mars successfully normalizes scheduled care.

Catalyst path is data-dependent over 1-3 months: look for appointment-booking, wellness-plan sign-ups, and feline share of visits at Mars networks. Over 6-18 months, the structural upside is modest but real if this becomes a repeatable customer-acquisition channel for cat owners, especially given cats’ lower visit frequency versus dogs. Contrarian view: this may be mostly low-ROI brand spend in a category where price sensitivity and inertia are the real constraints; without evidence of sustained visit lift, the equity read-through is probably overestimated.

Key Decisions for Investors

• No immediate trade on the PR itself; treat as a watch item until Mars/VCA data show a measurable lift in feline visit frequency or wellness-plan conversion.
• If follow-through data appears, add to IDEXX (IDXX) on weakness over the next 1-3 months; the best risk/reward is from incremental diagnostic utilization, not sentiment alone.
• Consider a small long ZTS / short a lower-quality pet-services or retail proxy if evidence emerges that preventive-care normalization is increasing medicalized spend at the expense of commoditized pet categories.
• Set a falsifier: if feline visit cadence and wellness enrollment do not improve over the next two quarters, fade any market narrative that this campaign is a meaningful growth driver.